The journal retracts the 29 January 2020 article cited above.
Following publication, concerns were raised regarding the integrity of the images in the published figures. The authors failed to provide a satisfactory explanation during the investigation, which was conducted in accordance with Frontiers’ policies. As a result, the data and conclusions of the article have been deemed unreliable and the article has been retracted.
This retraction was approved by the Chief Editors of Frontiers in Pharmacology and the Chief Executive Editor of Frontiers. The authors agree to this retraction.
Summary
Keywords
Carcinogenesis, neutrophil phenotype, Doxorubicin (Dox), Berberine, chemotherapeutic resistance
Citation
Frontiers Editorial Office (2023) Retraction: Berberine maintains the neutrophil N1 phenotype to reverse cancer cell resistance to doxorubicin. Front. Pharmacol. 14:1349235. doi: 10.3389/fphar.2023.1349235
Received
04 December 2023
Accepted
04 December 2023
Published
07 December 2023
Approved by
Olivier Feron, Université catholique de Louvain, Belgium
Volume
14 - 2023
Updates
Copyright
© 2023 Frontiers Editorial Office.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Editorial Office, research.integrity@frontiersin.org
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.